Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (250)

« Back to Publications

Heterologous mucosal vaccine boosting enhances mucosal and systemic immunity by distinct mechanisms.

Bissett C. et al, (2026), J Exp Med, 223

Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial.

Kelly E. et al, (2026), J Infect, 92

Time to tackle vaccine-HLA associations with artificial intelligence.

Mentzer AJ. et al, (2026), Lancet Infect Dis, 26

Early lymph node T follicular helper cell signalling hub drives influenza vaccine response in an ancestrally diverse cohort.

Siu JHY. et al, (2025), EBioMedicine, 122

Drivers of Crimean-Congo Hemorrhagic Fever in Natural Host and Effects of Control Measures, Bulgaria.

Limon G. et al, (2025), Emerg Infect Dis, 31, 1738 - 1746

Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial.

Janani L. et al, (2025), J Infect, 91

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006).

Li G. et al, (2025), Vaccine, 62

MAIT and other innate-like T cells integrate adaptive immune responses to modulate interval-dependent reactogenicity to mRNA vaccines.

Amini A. et al, (2025), Sci Immunol, 10

Dosing interval is a major factor determining the quality of T cells induced by SARS-CoV-2 mRNA and adenoviral vector vaccines.

Murray SM. et al, (2025), Sci Immunol, 10

Age differences in immunity to human seasonal coronaviruses and the immunogenicity of ChAdOx1 nCoV-19 (AZD1222).

Belij-Rammerstorfer S. et al, (2025), EBioMedicine, 118

Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil.

Costa Clemens SA. et al, (2025), Mayo Clin Proc Innov Qual Outcomes, 9

Nipah virus vaccines evaluated in pigs as a 'One Health' approach to protect public health.

McLean RK. et al, (2025), NPJ Vaccines, 10

Safety and immunogenicity of a bivalent Ebola virus and Sudan virus ChAdOx1 vectored vaccine in adults in the UK: an open-label, non-randomised, first-in-human, phase 1 clinical trial.

Jenkin D. et al, (2025), Lancet Microbe, 6

Complement-mediated enhancement of SARS-CoV-2 antibody neutralisation potency in vaccinated individuals.

Mellors J. et al, (2025), Nat Commun, 16

Ebola disease: bridging scientific discoveries and clinical application.

Rojek A. et al, (2025), Lancet Infect Dis, 25, e165 - e176

Load More

1
2
3
4
5
6
7
...
»